Update in stinging insect hypersensitivity

Area of Science:

• Allergy and Immunology
• Clinical Practice Guidelines
• Public Health Entomology

Background:

• Practice parameters for insect sting allergy are periodically updated by the ACAAI//AAAAI Joint Task Force.
• This review focuses on advances in diagnosis and management, including preparations for the 2026 update.

Purpose of the Study:

• To summarize recent developments in the diagnosis and management of insect sting allergy.
• To inform clinical practice based on updated evidence and ongoing research.

Main Methods:

• Review of published practice parameters and ongoing developments.
• Analysis of diagnostic testing (skin, serum IgE, venom component testing).
• Evaluation of risk factors, treatment indications, and duration of venom immunotherapy (VIT).

Main Results:

• Changes in stinging insect species and distribution noted in the US.
• Fatalities from insect sting allergy increased by 50% over 30 years.
• Diagnostic evaluation includes IgE testing, potentially venom component testing, and consideration of mastocytosis/hereditary alpha tryptasemia.
• VIT is indicated for high-risk patients (30-70% anaphylaxis risk), with rush regimens being safe.
• VIT duration varies, with 5 years being standard, but extended or indefinite treatment recommended for high-risk individuals.

Conclusions:

• Continued research refines the clinical approach to stinging insect hypersensitivity.
• Updated guidelines improve the diagnosis and management of insect sting allergy.
• Emphasis on personalized risk assessment for VIT indication and duration is crucial.